Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd has been downgraded from a Hold to a Sell rating as of 1 June 2026, reflecting a shift in technical indicators and valuation metrics despite its strong long-term returns. The company’s Mojo Score has declined to 42.0, with a corresponding Mojo Grade of Sell, driven primarily by deteriorating technical trends and concerns over flat recent financial performance.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a nuanced outlook for investors as the stock navigates recent volatility.

Gujarat Themis Biosyn Ltd experienced a notable intraday decline on 29 May 2026, touching a low of Rs 400.5, down 7.61% from previous levels. The stock underperformed its sector and broader market indices amid widespread selling pressure and a bearish market environment.

Gujarat Themis Biosyn Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable shift in technical indicators and sustained strong returns despite flat recent financial performance. The upgrade, effective from 27 May 2026, is driven by improvements in technical trends, solid management efficiency, and a robust long-term return profile, positioning the small-cap pharmaceutical firm as a more attractive proposition for investors seeking stability in a volatile sector.

The Sensex edged down by 0.08% on 27 May 2026, while Gujarat Themis Biosyn Ltd surged 7.23%, marking a notable outperformance of 6.65 percentage points over its Pharmaceuticals & Biotechnology sector. The stock also touched an intraday high of Rs 402.95, a 9.35% jump from its previous close, underscoring a strong single-session performance that demands a closer look at the underlying technical and market context.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators present a complex picture, with bullish signals on weekly charts contrasting with some bearish monthly trends. This article analyses the latest price movements, technical indicators, and market context to provide a comprehensive view for investors.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 25 May 2026. This change reflects a combination of flat recent financial performance, expensive valuation metrics, and a shift in technical indicators signalling caution for investors.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day change of 4.99%, the company’s overall technical trend has transitioned from mildly bullish to sideways, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 May 2026.

Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical company with a market capitalisation of ₹4,271 crores, reported a challenging fourth quarter for FY26, with net profit declining 9.25% quarter-on-quarter to ₹10.89 crores despite revenue reaching a quarterly high of ₹44.23 crores. The stock surged 4.99% to ₹387.25 following the results announcement, though it remains 19.23% below its 52-week high of ₹479.45.

The Sensex advanced 1.25% on 25 May 2026, yet Gujarat Themis Biosyn Ltd outpaced the broader market with a 7.28% gain, reaching an intraday high of Rs 401.3. This 6.59-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 19 May 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality, signalling a cautious but positive outlook for investors amid mixed performance data.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is reflected in a range of technical indicators, including MACD, Bollinger Bands, and moving averages, signalling a cautiously optimistic outlook for investors amid mixed monthly signals.

Gujarat Themis Biosyn Ltd experienced a notable decline today, touching an intraday low of Rs 344.4, reflecting a sharp price pressure of -7.31% as the stock underperformed its sector and broader market indices amid a cautious trading environment.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.